Please ensure Javascript is enabled for purposes of website accessibility
Contáctenos Contáctenos
ES
Inicio > Productos > Anticuerpos > Anticuerpos Primarios

Anti-Obinutuzumab Polyclonal Antibody (AY257014)

Datasheet Compartir producto Copiar información
Precio(USD):
Especificación:
  • 50ug
  • 100ug
  • 1mg
Número:
Contáctenos

  • Vista general

  • Imágenes

  • Referencias

  • Datasheet

  • SDS

Vista general
Número de catálogoAY257014
Descripción
Anti-Obinutuzumab Polyclonal Antibody (AY257014) is a rabbit polyclonal antibody detecting Obinutuzumab in ELISA.
Highlights
  • ●Affinity Purified — Minimal background and high purity for reliable results.
Reactividad de especiesGeneral
AplicacionesELISA
Especie huéspedRabbit
ClonalidadPolyclonal
IsotipoIgG
Inmunógeno Obinutuzumab
Objetivo Rabbit polyclonal to Gazyva.
Especificidad The product is specific for Obinutuzumab. This antibody serves as an excellent positive control for Obinutuzumab immunogenicity (ADA) assays.
Nivel de endotoxinas Please contact with the lab for this information.
Pureza >90% as determined by SDS-PAGE.
Purificación Purified by antigen affinity column.
Número de acceso CAS: 949142-50-1
Forma Liquid
Buffer de almacenamiento 0.01M PBS pH 7.4

Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Información de uso del producto
Aplicación Dilución
ELISA 1:5000-1:20000
IHC 1:50-1:500
WB 1:500-1:2000
Estabilidad y almacenamiento Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
FondoObinutuzumab is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment. It was approved under the trade name Gazyva by the US FDA in 2013, and as Gazyvaro by the EMA in Europe, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients, and as a second line treatment for follicular lymphoma. Obinutuzumab is a fully humanized monoclonal antibody that binds to an epitope on CD20 that partially overlaps with the epitope recognized by rituximab. Obinutuzumab binds to CD20 on B cells and causes these cells to be destroyed by engaging the adaptive immune system, directly activating intracellular apoptosis pathways, and activating the complement system.
Nota For research use only.
Imágenes
Referencias
Datasheet
Download SDS PDF
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recomendación

Contáctenos para cotizaciones personalizadas, solicitudes en masa y cualquier otro problema.

Correo: [email protected]

Lista de distribuidores

Obtener una cotización gratuita
Anti-Obinutuzumab Polyclonal Antibody

Acceso rápido

Contáctenos

  • +86-027-65523339

  • [email protected]

  • Edificio C, No. 666, Calle Shendunsi, Wuhan, 430206, China

  • linkedin
  • Ins
  • youtube
  • youtube
Derechos de autor © 2026 abinScience. Todos los derechos reservados. Todos los productos son solo para uso de investigación